We read with interest the commentary by Gerald Zavorsky and Colin Borland on our paper on lung diffusion for nitric oxide (DLNO) vs lung diffusion for carbon monoxide (DLCO) in normal subjects and in patients with heart failure. 1 Both authors are worldwide recognised experts. We are therefore indebted with them for the time and thought they gave to our work. The criticisms that they raise are both methodological and physiological. Indeed, DLNO measurement for clinical purposes has been introduced only a few years ago since the commercial apparatus has been available. Studies about simultaneous DLNO/DLCO evaluation have been conducted with different analysers and different NO concentrations so the method is still far from being standardised. However, we recognise that our DLNO values in normal subjects, obtained in a sizeable number of subjects, are lower than those previously reported by Zavorsky et al. 2 In any case the apparatus we used (Jaeger/Vyasis PFT Masterscreen) was calibrated for gas analysis using automated procedures and the linearity of analysers was factory checked. The formula used is:
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Moreover DLCO and DLNO were measured simultaneously, i.e. with the same manoeuvre, and DLCO values we obtained were, in normal subjects, about 100% of predicted values, which is a confirmation that the manoeuvre was correctly performed. In a recent paper, Hughes et al. 3 have reviewed this matter and reported in normal subjects quite different DLNO values among authors, ranging from 40 AE 6.7 mmol min À1 kPa À1 (equivalent to 120 AE 20.1 ml min À1 mm Hg À1 ) by Degano et al. 4 35 AE 12 mmol min À1 kPa À1 (equivalent to 105 AE 36 ml min À1 mm Hg À1 ) by Dressler et al. 5 and 70 AE 6.1 mmol min À1 kPa À1 (equivalent to 210 AE 18.3 ml min À1 mm Hg À1 ) by Zavorsky et al. 6 The DLNO we measured was 88.6 AE 20.5 ml min À1 mm Hg À1 (equivalent to 29.5 AE 6.8 mmol min À1 kPa À1 ). Moreover Hughes et al. 3 reported that the DLNO/DLCO average ratio ranged between 5.4 7 and 3.8 5 and we calculated 4.1 AE 0.7. 1 Differences in methodology, analysers, breath hold time and population might account for this variability.
Concerning breath hold time, we used 4 s, which is the same as Aguilaniu et al. 8 used whose data were the basis of the normal standards for European equations for carbon monoxide (CO) and nitric oxide (NO). Anyway, with a longer breath hold time we would expect an underestimation of DLNO, as reported by Dressler et al., 9 and not an overestimation as suggested by Zavorsky and Borland. In fact as breath hold time is increased, NO expiratory concentration reduces, reaching the detection limit of the NO analyser. This is an issue when using electrochemical sensors, as we 1 and others did, 2, 5, 8 and not with a highsensitivity chemiluminescence NO analyser as other authors did. 10, 11 As regards the membrane diffusion for carbon monoxide (DmCO), membrane diffusion for nitric oxide (DmNO) and capillary volume (Vcap), we prefer to call the capillary volume Vcap and not Vc as frequently done to avoid confusion with the vital capacity, and we do not agree with the Zavorsky and Borland critique. We recognise, however, that we erroneously quoted, and always have done so previously, the original paper by Roughton and Forster 12 but actually used the more recent description of DLCO partitioning. 13 Moreover the values we obtained in heart failure patients are in the same range of the values reported in several previous papers. [14] [15] [16] [17] [18] [19] [20] [21] It is true that Puri et al. 22 showed an increased Vcap and a very low Dm in patients with severe heart failure. However this observation was never replicated in several studies which we [14] [15] [16] [17] [18] [19] [20] [21] and others did. [23] [24] [25] In severe heart failure patients, Dm and Vcap and therefore Dm/Vcap, are extremely sensitive to physical exercise and mental stress. Indeed, we reported an increased Vcap, reduced Dm and a reduced Dm/Vcap in heart failure patients even one hour after exercise. 18, 20 It should be noted that, when doing resting Dm and Vcap measurement, we always bring the patient to the laboratory on a wheelchair and care is taken that he/she has no physical or mental stress before and during DLCO measurement. Indeed, even walking can be a relevant exercise in severe heart failure patients. This part of the methodology was not reported in the Puri et al. 22 paper which, we recognise, was a pioneering report on the topic. It is possible that the very cautious approach that we used was not taken in the Puri et al. laboratory and therefore their data resemble more our post-exercise data than a true measurement at rest. However, this is just a possibility which we raise based on our 'on field' experience. Finally, we have previously reported that in severe heart failure patients the Dm/ Vcap ratio is actually increased, albeit a reduced DLCO. 16 This probably means that in severe heart failure there are few alveolar capillary units which are at work, as suggested by low alveolar volume, but the few at work are performing well. 16 This is similar to what happens in kidney disease. 26 It should also be noticed that the DmCO data are highly comparable with the DmNO data we measured, supplying further evidence that our calculations were correct. This is not the case for the recalculation done by Zavorsky and Borland on our data who report a relevant difference between DmNO and DmCO when recalculating our data. We have to admit that we were not able to repeat the calculation done by Zavorsky and Borland using the yNO and yCO values they supplied in the table legend (in reality there must be a typo as yNO and yCO were reported in the legend but only yNO ¼ 4.5 ml ml À1 mm Hg À1 min À1 in the table). In this regard the presence of a defined yNO value, 27 albeit a fascinating issue, is still a matter of debate. 3 Indeed Hughes et al. specifically wrote: 'Borland et al. estimated that 37% of the resistance to NO uptake lies in the 1/y.Vc component, but this figure must be treated with caution as it involved exchange transfusion in dogs, substituting bovine Hb-glutamer 200 (cell-free blood substitute) for whole blood'. 3 Moreover, Hughes et al. conclude that 'at the present time, each laboratory should establish its own standard for the TLNO/TLCO (DLNO/DLCO) ratio in healthy subjects although the current consensus is that the ratio is in the range of 4.3-4.9'. 3 We calculated values in 50 healthy subjects at 4.1 AE 0.7 and 4.4 AE 0.8 in chronic heart failure patients.
However, we also recognise that DmCO and Vcap values which we measured with the Roughton and Forster revised method have a large standard deviation. As an average, data of DmCO were similar to the data of DmNO with a calculated alpha correction factor of 2.63 and 2.75 in healthy and heart failure patients, respectively. Notably the value in healthy subjects we calculated is similar to that previously reported by different authors 28, 29 while this calculation has never been done before in heart failure patients. The Dm value is very different when our data were recalculated using a finite value for yNO as Zavorsky and Borland did. Moreover, the yNO value used by Borland was only recently proposed 30 and no consensus has been reached on this. 3 Finally, it is true that we stated that Vcap was unchanged between heart failure and normal subjects. We meant, in reality, that no statistical difference was found and indeed the average data were 85.8 AE 36.7 ml and 90.4 AE 27 ml. Moreover the DLNO/DLCO ratio in heart failure patients vs healthy subjects was 4.4 AE 0.8 and 4.1 AE 0.7 (p ¼ 0.06), a quantitatively small difference. Therefore if DLNO/DLCO Â yVcap is used to calculate Dm then its value was the same between healthy and heart failure patients and not higher in heart failure patients as was stated (28.2 AE 9 ml min À1 mm Hg À1 for healthy and 28.1 AE 11.6 ml min À1 mm Hg À1 for heart failure patients). So our measurements do not confirm the statement that DmNO we measured 'was higher in heart failure a finding certainly wrong'. However, we recognise that by this calculation Dm was the same in the two groups, a finding different from that calculated by the Roughton and Forster method. Several findings may explain this, but first of all note that the standard deviation was huge. This finding casts some doubt about the practical use of simultaneous measurements of DLNO and DLCO to estimate Dm and Vcap, at least till a certain value for yNO is available. Indeed, DLNO/DLCO is certainly related to Dm/Vcap, 3 but the precision of this proxy is still unknown and in our hands questionable.
In conclusion we are grateful to Zavorsky and Borland for the thought that they dedicated to our work but we believe that we are still far away from the possibility of a practical use of DLCO/DLNO, and of DmNO in the clinical field of heart failure. Ours was the first report on the topic and obviously more data are needed to confirm, or not confirm, our findings.
